Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal BOTOX for Facial Fine Lines
NCT04631588Phase 1Completed
- Sponsor
- Allergan
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of onabotulinumtoxinA in facial rhytides (3 arms), sponsored by Allergan. Primary endpoints: Number of Participants with Adverse Events (AEs), Number of Participants with Potential Clinically Significant (PCS) changes in vital signs and 2 more. Started Nov 2020; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
facial rhytides
Beyond the preview
Go deeper on NCT04631588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631588.